Log In
Print
BCIQ
Print
Print this Print this
 

RPC4046

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionRecombinant humanized mAb against interleukin-13 (IL-13)
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationEosinophilic esophagitis
Indication DetailsTreat eosinophilic esophagitis (EoE)
Regulatory Designation

Partner

Receptos Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today